Next Phase Newsletter

A biotech company based in the USA has an active pipeline of therapeutic assets in immuno-oncology and autoimmune diseases. The firm has been seeking novel therapeutics opportunities that are synergistic with the firm’s existing pipeline for potential licensing, investment, and other partnership opportunities. The firm is most interested in opportunities based in US and Europe.

The firm is seeking therapeutic opportunities for potential licensing, investment, and other win-win partnership opportunities. The firm is open to novel targets and modalities; in terms of indication/disease area, the firm is only considering immuno-oncology and autoimmune diseases at this time. In terms of stage of development, the firm will primarily consider pre-clinical stage assets.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly formed corporate VC of a pharmaceutical company is investing from an evergreen fund. The firm is interested in investing in companies in therapeutics, AI/ML drug discovery tools, digital therapeutics, virtual care platforms and connected devices. For therapeutics companies, the firm prefers to invest in companies that are preclinical, before IND. For other companies, the firm prefers to invest close to revenue, post pilot. The firm invests in companies based in North America, Europe and Israel from pre-seed to Series A, and will invest between .5-4M EUR in their first round, with capital reserved for follow on investments.

Historically, the firm has focused on CNS disorders and rare diseases, including areas such as neurodevelopment, epilepsy and mental health. The firm is investing in this area, with an additional focus on pregnancy, childbirth and women’s health.

The firm takes at minimum a board observer seat when investing, and look to help the company strategically with their expertise and network.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital/private equity firm based in the US invests in both digital health technologies and the life sciences. For their life sciences investments, most of them are in therapeutics, with about 5% of their investments going to life science tools and diagnostics. For therapeutics companies, the firm prefers to see efficacy and safety data before investing. For tools, diagnostics and digital health companies, the companies should be either revenue generating, or, at minimum, revenue in sight. The firm will consider global opportunities, but invests primarily in the US, and generally invests 5-15M in their early stage deals.

For therapeutics companies, the firm is modality and indication agnostic, although is less interested in microbiotic-related therapeutics. The firm prefers platform technologies, or an associative program; they do not invest in single assets. For digital health companies, the firm invests primarily in enterprise software, such as clinical data management, tools to enable better care and healthcare IT companies.

The firm generally leads or co-leads investments, and will take a board seat after investing. For therapeutics companies, the firm prefers the startups to have raised 1-5M in a previous round before investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm focuses its investments on data moat and network effect. The firm currently manages over $1B AUM and since inception, has invested in over 260 companies from seed to growth stages and continues to seek investment opportunities across the globe.

Within life sciences and healthcare, the firm invests in digital health and technologies that leverage AI, big data, and other applications in the intersection of science and technology. While the firm does not typically invest in traditional therapeutics, but has invested in medical device and diagnostic companies in the past. In terms of stage of development, the firm is open to the earliest stages of development and is agnostic towards indication area.

The firm seeks to work with dedicated, experienced management teams. The firm is open to working with first time entrepreneurs, and often acts as the first institutional investor. The firm is open to either acting as a lead or co-investor, and seeks board representation when leading.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A pharmaceutical company headquartered in Asia has 40 branches and subsidiaries around the world (including the United States, Japan, Germany, Russia, Spain, India, etc.). The firm’s main business covers chemical and biological medicines, pharmaceutical packaging, and trading.

The firm’s investment subsidiary is responsible for equity investment and in-licensing activities for its corporate parent.

The firm is most interested in companies developing novel drugs in Biologics, Cell therapy, Gene therapy, Repurposed drugs, and Biosimilars. The firm is interested in distribution rights in China. In terms of stage of development, companies that are at or before the NDA stage are preferred (Pre-clinical, Phase I, Phase II, Phase III, NDA).

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global investment firm with bases in USA and Asia is primarily focused on healthcare investments and looks to make allocations ranging from $1M to $40M depending on opportunity and risk/reward. The firm is actively seeking new investments and is open to review opportunities from around the globe.

Within the life science space the firm is interested in Therapeutics, Medical Devices, and Diagnostics. The firm is currently most interested in companies with some clinical data however they are open to reviewing pre-clinical stage opportunities as well. The firm is open to biosimilar and repurposed assets, and has a preference for platform technologies but is also open to considering single asset opportunities. The firm is open to review all classes of medical devices and diagnostics. The firm is entirely open in terms of indication.

The firm is open to investing in both private and publicly held companies and is currently very interested in making cross over investments. The firm is also very interested in companies that have a plan or ability to enter the Chinese market as the firm can add significant value with this strategy. The firm is open to acting as both a lead and co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm focuses on early-stage diagnostics, life science research tools, and biotech-related companies. The firm’s target initial investment size is $1-$2M. The firm prefers to act as the co-investor with other types of investors such as strategic partners. The firm invests in companies that are based in the US. The firm is actively seeking new investment opportunities.

In the life sciences, the firm is currently seeking to invest in early-stage diagnostics, life science research tools, and biotech-related companies. The firm will invest in a limited number of therapeutic opportunities.  The firm is opportunistic in terms of subsectors and indications. The firm will consider investing in companies that have strong intellectual property protection and provide barriers to competitive entry. The firm also seeks companies with potential large addressable markets, which typically have the potential to generate at least $50M of annual revenues.

The firm backs management teams that listen to the market, develop new products to provide customer value by meeting unmet needs and/or delivering an order of magnitude improvement to the customer. They focus on CEOs that are driven to deliver exceptional investment returns to both investors and management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.